Atria Wealth Solutions Inc. acquired a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 48,881 shares of the financial services provider’s stock, valued at approximately $6,369,000. Atria Wealth Solutions Inc. owned approximately 0.08% of iShares Biotechnology ETF at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the company. Citigroup Inc. grew its holdings in shares of iShares Biotechnology ETF by 23.6% in the first quarter. Citigroup Inc. now owns 1,973,585 shares of the financial services provider’s stock worth $257,158,000 after purchasing an additional 376,498 shares during the last quarter. UBS Group AG grew its holdings in iShares Biotechnology ETF by 10.9% in the 1st quarter. UBS Group AG now owns 2,005,796 shares of the financial services provider’s stock worth $261,355,000 after acquiring an additional 196,343 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of iShares Biotechnology ETF by 29.5% during the first quarter. JPMorgan Chase & Co. now owns 626,866 shares of the financial services provider’s stock valued at $81,680,000 after acquiring an additional 142,937 shares during the last quarter. Mmbg Investment Advisors CO. purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth about $12,978,000. Finally, Tredje AP fonden bought a new stake in shares of iShares Biotechnology ETF in the first quarter worth about $9,121,000. Institutional investors own 60.42% of the company’s stock.
iShares Biotechnology ETF Stock Up 1.1 %
IBB opened at $128.40 on Monday. iShares Biotechnology ETF has a one year low of $104.29 and a one year high of $175.29. The business has a 50 day simple moving average of $125.44 and a two-hundred day simple moving average of $122.53.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here’s Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.